Readmission with respiratory syncytial virus (RSV) infection among graduates from a Neonatal Intensive Care Unit

Pediatric Pulmonology

Volumn 34, Issue 4, 2002, Pages 262-266

  McCormick, Jonathan ^a   Tubman, Richard ^a  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

Author keywords

Bronchiolitis; Cost effectiveness; Epidemiology; Medical economics; NICU; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; COST BENEFIT ANALYSIS; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN INTENSIVE CARE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; SEASONAL VARIATION; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; IRELAND; MALE; MEDICAL AUDIT; PATIENT READMISSION; PROBABILITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK;

EID: 0036786028     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10169     Document Type: Article

References (10)

1. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-1507.
2. Noble V, Murray M, Webb MSC, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997;76:315-319.
3. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
4. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000;83:313-316.
5. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-427.
6. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000;19:1068-1071.
7. Northern Ireland Statistics and Research Agency. 1998. Northern Ireland annual abstract of statistics. National statistics publication. p 18.
8. Northern Ireland Statistics and Research Agency. 2000. Northern Ireland annual abstract of statistics. National statistics publication. p 51.
9. Nicholl RM. RSV prevention. Arch Dis Child 2000;82:88-90.
10. Sharland M, Bedford-Russell A. Preventing respiratory syncytial virus bronchiolitis. Br Med J [Clin Res] 2001;322:62-63.